AstraZeneca's Fasenra set to revolutionize COPD treatment

UK pharma major AstraZeneca’s (LSE: AZN) Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 JP Morgan Healthcare Conference, is set to transform the chronic obstructive pulmonary disease (COPD) treatment.

As the first interleukin (IL)-5-targeting monoclonal antibody in late-stage trials, Fasenra targets eosinophilic inflammation, potentially reshaping treatment standards and reinforcing AstraZeneca’s leadership in respiratory and immunology innovations for this unmet medical need, according to pharma analytics company GlobalData.

COPD, a progressive condition affecting millions globally, has historically relied on inhaled therapies. However, biologics like Sanofi (Euronext: SAN) and Regeneron’s (Nasdaq: REGN) Dupixent (dupilumab) have paved the way for a new treatment paradigm, targeting specific inflammatory pathways to reduce exacerbations and improve patient outcomes. Fasenra, already approved for severe asthma, builds on this progress with its ability to address eosinophilic inflammation, a key driver in a subset of COPD patients.